Introduction
============

Chronic obstructive pulmonary disease (COPD) is the fifth leading cause of death in the world and the mortality rate is expected to increase more than 30% during the next 10 years.[@b1-copd-7-297] Acute exacerbations of COPD (AECOPD) are common and are a key predictor of increased morbidity, health care costs, and mortality. The Global Initiative for Lung Disease (GOLD)[@b1-copd-7-297] defines a COPD exacerbation as "an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum that is beyond normal day-to-day variation, is acute in onset, and may warrant a change in regular medication in a patient with underlying COPD". Most patients with COPD have at least one exacerbation per year; a substantial proportion of patients (17%) have three or more episodes per year.[@b2-copd-7-297],[@b3-copd-7-297]

Many exacerbations of COPD are managed on an outpatient basis, but if the patient is hospitalized, the length of stay (LOS) is prolonged: the median LOS in Canadian hospitals is 13 days,[@b4-copd-7-297] which translates to an estimated cost of CAD\$9500 per hospitalization.[@b5-copd-7-297] Premature discharge resulting in shorter LOS, however, is associated with increased readmission and mortality.[@b6-copd-7-297]

Hospitalization to treat acute illness can have a detrimental effect on muscle performance.[@b7-copd-7-297] Muscle impairment and functional decline have been well-documented in older hospitalized patients, and have been attributed to the consequences of hospitalization rather than the admitting illness.[@b8-copd-7-297]--[@b11-copd-7-297] In a previous study on 1181 hospitalized patients with acute medical illnesses (circulatory, 27%; respiratory, 20%; gastrointestinal, 15%; cancer, 6%), 17% of patients required assistance with mobility on discharge, despite being able to walk independently prior to admission.[@b12-copd-7-297] Pitta et al reported that patients who are hospitalized with an acute exacerbation of COPD spend the majority of their time sitting, and do not return to their baseline level of activity even after 1 month post-discharge.[@b13-copd-7-297]

Caring for hospitalized patients with AECOPD can be complicated by the presence of other chronic conditions, which can also influence the severity of the exacerbation and the health outcomes of the patient. Individuals with COPD have a higher risk of multimorbidity[@b14-copd-7-297]--[@b27-copd-7-297] ([Table 1](#t1-copd-7-297){ref-type="table"}) than individuals with other chronic illnesses. Despite this, there has been widespread failure to address the complexities inherent in living with multiple chronic illnesses simultaneously, especially in the hospitalized, acutely ill population. Devising exercise plans for hospitalized AECOPD patients living with multimorbidity is complicated by the limitations imposed by the acute exacerbation and by the synergistic effect of the multiple conditions upon the person. While recent reviews have examined evidence regarding the effectiveness of exercise therapy for people with multimorbidity in community settings,[@b28-copd-7-297],[@b29-copd-7-297] none have focused on hospitalized patients with COPD who also experience multi-morbidity. National physical activity guidelines fail to address this issue as well.[@b30-copd-7-297],[@b31-copd-7-297]

Systematic reviews (SRs) provide a high level of evidence regarding the efficacy of therapeutic intervention, but the sheer number of available SRs on a given topic can make it difficult for the clinician to distill the important messages. Systematic reviews of systematic reviews have been purported as a way to both evaluate and summarize the key messages on important therapies, and are commonly published in areas of health care.[@b32-copd-7-297]--[@b36-copd-7-297] The aim of the current research was to synthesize the relevant literature on the benefits of exercise for people with multimorbidity who are experiencing an AECOPD. Thus we posed the question: What are the parameters and outcomes of exercise in AECOPD and in commonly associated comorbidities as reported by SRs?

Methods
=======

Search strategy
---------------

A systematic review was performed using the methodology outlined by the Cochrane Collaboration protocol.[@b37-copd-7-297] Electronic databases were searched up to July 2011 including the Cochrane Controlled Trials Register, Cochrane-Systematic Reviews, MEDLINE, CINAHL (Cumulative Index to Nursing and Allied Health Literature), SPORTDiscus, EMBASE, PEDro (Physiotherapy Evidence Database), PsycINFO, and EBM reviews. Gray literature and reference lists from relevant articles were also reviewed to identify additional articles. Search terms were exemplified by the MEDLINE search strategy ([Appendix 1](#app1-copd-7-297){ref-type="app"}) and were modified accordingly to fit the requirements of the other databases.

Study criteria
--------------

Articles were included if they (1) described participants with AECOPD or COPD, or had one or more of the following conditions that are common comorbidities: anxiety/depression, atherosclerosis, ischemic heart disease, peripheral vascular disease, heart failure, hypertension, diabetes mellitus, human immunodeficiency virus (HIV/AIDS), osteoarthritis (OA), osteoporosis, obesity/overweight, or older adults; (2) were SRs that included at least one randomized controlled trial (RCT); (3) examined an exercise intervention of aerobic training (AT), resistance training (RT), balance training (BT), or a combination thereof; (4) included at least one outcome of fitness; (5) had comparison groups of exercise training versus control/sham (that consisted of usual treatment, no exercise, or attention placebo); (6) were published in English. Articles were excluded if they (1) were published before 2000, or (2) investigated tai chi, yoga, or qi gong due to the multiple forms of these exercises and the difficulty in defining the expected training response to fitness outcomes. If two SRs reported on the same question and the majority of papers included were the same, only the SR with more articles and a more comprehensive review was included. Also, several SRs did not contain meta-analyses. These were reviewed if they met the criteria above, but data were extracted only if other reviews with meta-analyses were not available on the outcomes of interest.

Two individuals independently screened all titles and abstracts retrieved. Any discrepancies were discussed and resolved. From the selected abstracts, one person screened 362 full text articles to determine if they met the inclusion criteria using a screening form. A second person was consulted to confirm agreement on all articles to be excluded. The flow chart of the search strategy and study selection is summarized in [Figure 1](#f1-copd-7-297){ref-type="fig"}.

For each condition, one of the coauthors abstracted data and performed the quality assessment, which was double-checked by at least one person. All discrepancies were discussed and reconciled. Data abstracted, when available, included (1) condition, age, and gender of participants, (2) the modality (Mo), frequency (Fr), intensity (I), time of session (T), and duration of program (D) of the exercise intervention, (3) descriptors of the control, placebo, or sham group, and (4) outcomes of fitness, disease control or prevention, quality of life, and function.

Data related to functional training was abstracted. Functional training can be defined as mobility exercises that are functionally- or task-based rather than focused on strength training of particular muscle groups or endurance training to improve cardiovascular or aerobic status. Examples are stair climbing, repetitive sit to stand, and transfers. Such training often includes a combination of strength, endurance, and balance.

Quality assessment
------------------

All SRs were assessed using the AMSTAR quality assessment tool.[@b38-copd-7-297] Scores for each item and totals are reported. Item 11 was scored as "yes" if the conflict of interest was stated for the authors of the SR.

Data synthesis
--------------

Data was synthesized in tables that described the study quality ([Table 2](#t2-copd-7-297){ref-type="table"}), the participants and interventions ([Table 3](#t3-copd-7-297){ref-type="table"}), and outcomes ([Table 4](#t4-copd-7-297){ref-type="table"}). An outcome was assigned to one of two categories based on whether it was measured in several conditions or if it was applied to evaluate a disease specific marker: (1) generic fitness (eg, exercise capacity, strength), quality of life, and functional outcomes (eg, timed up-and-go test, stair climbing), and (2) disease specific fitness, control, and prevention outcomes (eg, dyspnea, mortality, pain, ejection fraction, cholesterol levels).

Only statistically significant outcomes are reported in [Table 4](#t4-copd-7-297){ref-type="table"}. When available, quantitative data for each metaanalysis was described including the number of studies, the number of participants, the standardized effect size or weighted mean difference, risk ratio, odds ratio, and 95% confidence intervals. If this information was not available, an attempt was made to determine the number of studies that reported a significantly positive change versus the total number of studies that measured the outcome. Nonsignificant findings or trends are not reported.

Results
=======

Study selection
---------------

A search of the eight databases yielded 3276 citations and abstracts after duplicates were removed. After independent screening of the citations by two reviewers, 362 full-text articles were selected and reviewed for inclusion. Fifteen additional articles were identified from manual searching of reference lists. The main reasons for excluding articles were that they were not an SR, that participants did not have COPD/AECOPD or one of the other conditions of the search strategy, there was no exercise intervention, the exercise intervention was not clearly described or not differentiated from concurrent treatment, there was no comparison between an exercise group and a control group, the SR reported on similar data but had few articles, the article was not available in English, or the article was published before 2000. No SRs were identified that compared exercise to a control group in people with asthma or bronchiectasis. Fifty-eight SRs met the inclusion criteria.

Quality assessment
------------------

The number of RCTs in any of the SRs that related to our question ranged from 4 to 83. The average AMSTAR score was 7.5 out of a potential 11. The most common items not reported were a list of excluded articles (only 26% of SRs provided this list), an examination of publication bias (ie, funnel plot or Egger regression test, which 45% reported), a statement regarding conflict of interest (50% reported), a selection and abstraction of data performed by two reviewers (65% reported), and a search of the gray literature (59% reported). All other items were addressed by ≥71% of the SRs.

Characteristics of participants
-------------------------------

The age of participants ranged between 18 years and the "very elderly". SRs that described people with HIV or depression had the youngest participants. Gender varied from 100% male to 100% female. SRs that described older adults had the largest sample sizes.

Characteristics of interventions and outcomes in the different chronic conditions
---------------------------------------------------------------------------------

Characteristics of the interventions are detailed in [Table 3](#t3-copd-7-297){ref-type="table"}, while outcomes in the different chronic conditions are shown in [Table 4](#t4-copd-7-297){ref-type="table"}.

### AECOPD

One SR investigated the benefits of aerobic and resistance training in people with COPD (AMSTAR of 11).[@b39-copd-7-297] Aerobic and resistance training of the extremities improved walk distance performance and quality of life measures in addition to decreasing dyspnea, compared to the control group. Exercise also reduced admissions to hospital and mortality as demonstrated by meta-analyses of five and three RCTs, respectively.[@b39-copd-7-297] The SR included studies that initiated exercise immediately after or up to 6 weeks after treatment initiation for AECOPD as part of pulmonary rehabilitation on an out- or in-patient basis. Frequency of training ranged from three times a week to twice daily. The intensity of aerobic training was not reported.

### COPD (stable)

Six SRs investigated the benefits of AT and RT in people with COPD, and the AMSTAR scores ranged between 5 and 10.[@b40-copd-7-297]--[@b45-copd-7-297] AT and RT of the extremities improved maximal exercise capacity, walk distance performance, and quality of life measures in outpatient COPD compared to a control group as described by a high quality SR with an AMSTAR score of 10.[@b42-copd-7-297] Whether people with mild-to-moderate COPD with AECOPD benefit from exercise training is equivocal, as summarized by two SRs with AMSTAR scores of 5 and 8.[@b40-copd-7-297],[@b44-copd-7-297] Exercise training that focused on RT improved leg strength and cycling endurance as described by one review with an AMSTAR of 8.[@b43-copd-7-297] Unsupported and supported arm exercise showed improvement in half of the studies evaluated by one SR.[@b41-copd-7-297] Home exercise demonstrated improvement in exercise capacity in all studies that assessed this attribute and half of the studies that assessed quality of life.[@b45-copd-7-297] Dyspnea was significantly improved by aerobic and resistance trainings in two reports.[@b42-copd-7-297],[@b44-copd-7-297]

Walking and cycling were the most common AT whereas free weights and Theraband™ were the most common resistance used during RT. Frequency of training ranged from twice weekly to twice daily. The intensity of aerobic training was either not described in the SRs or, in one report, was quantified as a percentage of walk test distance.[@b45-copd-7-297] RT intensity ranged from one-third of a (repetition maximum) RM to near maximal intensity for the number of repetitions. The time for each session varied between 30 and 120 minutes, or was defined in terms of repetitions and sets for RT.[@b41-copd-7-297],[@b43-copd-7-297] Durations of studies ranged between four weeks and 18 months. There was an obvious focus on AT and RT in the SRs, and no reports described the outcomes from balance or functional training in people with COPD.

### Older adults

Overall, exercise training results in improved physical and functional performance for older adults, as demonstrated by seven SRs,[@b46-copd-7-297]--[@b52-copd-7-297] although initial health status influenced both the ability to participate in certain programs as well as the outcomes of the training. Most SRs and many RCTs included a mix of RT, BT, and functional training rather than focusing on a single type of training. Thus, evidence for the most part is provided from multifaceted training rather than a singular approach. Many other aspects of the training varied widely, with a training frequency most often of two to three times a week, total duration that ranged from 2 to 104 weeks, and a variable intensity level ([Table 3](#t3-copd-7-297){ref-type="table"}). SRs, which had AMSTAR scores ranging from 5 to 11, showed that mixed training improved balance[@b47-copd-7-297],[@b49-copd-7-297],[@b52-copd-7-297] and strength,[@b47-copd-7-297],[@b51-copd-7-297],[@b52-copd-7-297] reduced falls,[@b48-copd-7-297] and improved functional measures such as the 6-minute walk distance (6MWD).[@b46-copd-7-297],[@b49-copd-7-297],[@b51-copd-7-297],[@b52-copd-7-297] An SR that had a singular focus on RT with an AMSTAR of 11 showed widespread improvements in lower extremity strength, aerobic capacity, and several physical performance tests ([Table 4](#t4-copd-7-297){ref-type="table"}).[@b50-copd-7-297] In addition, this SR provided evidence that RT reduced the relative risk of death and pain.[@b50-copd-7-297]

### Heart failure

Six meta-analyses[@b53-copd-7-297]--[@b58-copd-7-297] investigated the benefits of AT and/or RT in patients with chronic heart failure. Most of these papers had AMSTAR scores ranging from 6 to 8, although one[@b57-copd-7-297] had a score of 3. Based on these papers, it can be concluded that AT and RT significantly improved numerous cardiopulmonary exercise outcomes, including increasing VO~2~ max, 6MWD, maximal workload, and anaerobic threshold. It also improved several cardiac system factors, including increasing the heart rate and cardiac output during maximal exercise, improving left ventricular ejection fraction, and the end-diastolic and end-systolic ventricular volume. Two meta-analyses also reported that exercise significantly improved quality of life in these patients.[@b55-copd-7-297],[@b58-copd-7-297]

There were no meta-analyses that investigated the role of AT and/or RT on muscle strength or endurance. Three reviews without meta-analyses investigated the benefits of exercise on a large number of outcomes, including several that are specific to muscle performance.[@b59-copd-7-297]--[@b61-copd-7-297] Exercise improved upper and lower extremity strength and muscle endurance, increased oxidative enzyme activity in the quadriceps muscle, and increased forearm blood flow. However, these results must be interpreted with caution as these reports were SRs without meta-analyses, and the AMSTAR scores were relatively low (2 to 6), with few details quantifying the magnitude of the effect.

The AT was relatively consistent across all the studies, in terms of frequency, mode, and intensity. Subjects exercised 2--7 days per week, with most trials within each SR providing the exercise intervention for 3 days per week. Cycle ergometry and treadmill walking were the most commonly used modalities. Most studies prescribed an AT intensity based on a maximal cardiopulmonary exercise test, with exercise intensities ranging from 50% to 80% of VO~2~ max. The time per session and the durations of the programs were very variable, ranging from 12 to 100 minutes and 1 to 14 months, respectively. Where described, the resistance training prescription tended to be based on 40% to 80% of one RM.

### Ischemic heart disease

Seven SRs investigated the benefits of early mobilization, anaerobic training, and/or RT in ischemic heart disease patients.[@b62-copd-7-297]--[@b68-copd-7-297] The AMSTAR scores ranged from 3 to 10, with two reviews having a score of 3,[@b63-copd-7-297],[@b67-copd-7-297] and one a score of 5.[@b68-copd-7-297] The remaining reviews had AMSTAR scores exceeding 8.

The study populations were predominantly male. There was variation in the specific type of intervention (both AT and RT), and differing endpoints were utilized to evaluate benefit and responses. Five reviews examined the effects of AT,[@b62-copd-7-297],[@b63-copd-7-297],[@b65-copd-7-297],[@b66-copd-7-297],[@b68-copd-7-297] three reported the effects of both AT and RT,[@b62-copd-7-297],[@b66-copd-7-297],[@b68-copd-7-297] one examined the sole effect of early in-hospital mobilization,[@b64-copd-7-297] and one examined the sole effect of RT.[@b67-copd-7-297] Some work focused on reporting disease-specific outcomes (ie, recurrent myocardial infarction, cholesterol and triglyceride levels, ejection fraction, and end-systolic and end-diastolic volumes),[@b62-copd-7-297],[@b64-copd-7-297],[@b65-copd-7-297],[@b66-copd-7-297] while others studied indices of overall activity and fitness (ie, walking distance, maximal aerobic capacity, exercise duration, and muscle strength)[@b63-copd-7-297],[@b67-copd-7-297],[@b68-copd-7-297] in these populations with ischemic heart disease. Quality of life and health care utilization were not studied or specifically reported, and significant variation was evident in the duration of follow-up.

Early in-hospital mobilization demonstrated nonsignificant trends towards decreased total mortality and nonfatal re-infarction.[@b64-copd-7-297] The results suggest that anaerobic and RT reduces the risk of total cardiac death, recurrent myocardial infarction, as well as cholesterol and triglyceride levels. Improvements were also demonstrated in peak oxygen uptake, exercise duration, exercise workload, and 6MWD. The findings suggest that benefits were greater when exercise programming was initiated soon after an ischemic event (as early as 1 week post-myocardial infarction), and when exercise program duration exceeded either 3 or 6 months (rather than \<3 months).

### Peripheral vascular disease

Exercise training significantly improved the walking distance and pain-free walking distance in patients with peripheral vascular disease (PVD) when compared to standard care as evidenced by two meta-analyses with relatively high AMSTAR scores of 9 and 7.[@b69-copd-7-297],[@b70-copd-7-297] Exercise training was generally supervised. The optimal intensity was not clear, although it was suggested that patients exercised until near maximal pain. The majority of the studies applied an exercise regimen of two to three times per week for 30--60 minutes, with these usually incorporating walking, leg exercises, or treadmill training. Some encouraged additional home exercise.

### Hypertension

Exercise training (mainly aerobic exercise) significantly lowered the systolic (SBP) and diastolic blood pressure (DBP) in people with hypertension, as supported by four meta-analyses.[@b71-copd-7-297]--[@b74-copd-7-297] Two of the SRs[@b73-copd-7-297],[@b74-copd-7-297] had AMSTAR scores of 8 of 11 while two others had scores of 7 and 4.[@b71-copd-7-297],[@b72-copd-7-297] VO~2~ max increased significantly and resting heart rate (HR) decreased after exercise training.[@b72-copd-7-297] Exercise training also demonstrated significant improvement in cardiovascular risk factors as shown by an increase in high density lipoprotein cholesterol, and decreases in glucose, insulin levels, and the homeostatic model assessment index (a measure of insulin resistance), despite the inclusion of normotensives in the analysis.[@b72-copd-7-297] Reductions were greater for SBP in African-- American individuals and for DBP in Asian individuals, but only a small number of trials were conducted in people of different ethnic backgrounds.[@b74-copd-7-297]

A variety of study designs were included in the meta-analyses, but the majority of the studies included training programs that involved mainly aerobic exercise (walking, jogging, cycling), usually three to five times per week, for 30 to 60 minutes, at moderate intensity. According to two SRs there is no relationship between blood pressure (BP) response and training characteristics (intensity, frequency), except for a lesser BP reduction associated with a longer total trial duration, probably due to loss of compliance in long trials.[@b72-copd-7-297],[@b74-copd-7-297]

Because aerobic exercise also showed positive effects in normotensives, these data suggest that aerobic exercise is an important strategy not only in treating high blood pressure, but could potentially be used as prophylaxis.[@b74-copd-7-297]

### Obesity

Data on the effect of physical activity on fitness outcomes in this population were limited. In post-menopausal obese women, an exercise-based program improved VO~2~ max as shown in one RCT reported by one SR.[@b75-copd-7-297] A Cochrane review with an AMSTAR score of 11 did not report the effect of physical activity on VO~2~ max but found a decrease in DBP, reduced triglycerides and glucose, and increased HDL levels.[@b76-copd-7-297] The majority of trials in the two SRs consisted of AT, usually two to three times per week, at 60%--80% of VO~2~ max or HRmax, with different durations utilized.

### Osteoarthritis

Results from the five SRs examining the effects of exercise on patients with knee or hip OA consistently show beneficial results for fitness levels and functional performance, though emphasis was primarily on disease-specific outcomes such as joint pain or physical dysfunction.[@b77-copd-7-297]--[@b81-copd-7-297] AMSTAR scores were between 7 and 9, and most studies failed to report publication bias or conflicts of interest.

Isotonic RT targeting the quadriceps or hamstrings muscle groups was the most common exercise intervention, though AT and range of motion exercises were also included. Control interventions primarily included patient education or usual care with no additional treatment. Most exercise interventions lasted 3--6 months, though some were as short as 4 weeks and as long as 24 months. Some studies required daily exercise, while others included only two or three sessions per week. Individual sessions were typically 45--60 minutes in length and complied with usual dosage characteristics for exercise in healthy populations (ie, three sets of ten repetitions for resistance training, and 50% to 80% of maximum heart rate for aerobic interventions).

Pain and physical function were consistently improved following exercise, but no particular type of exercise was found to be superior. Studies examining RT found improvements in strength compared to control interventions,[@b77-copd-7-297],[@b81-copd-7-297] while studies examining the effects of AT found improvements in aerobic capacity, walking speed, and walking distance.[@b77-copd-7-297]--[@b80-copd-7-297] All studies found exercise to be a safe and feasible intervention with minimal side effects for patients with OA.

### Osteoporosis

Most of the SRs identified in this study investigated the benefits of exercise in the prevention of osteoporosis or osteopenia in healthy, pre- or post-menopausal women. Two SRs investigated the impact of exercise in women diagnosed with osteoporosis or osteopenia, and these had AMSTAR scores of 7[@b82-copd-7-297] and 6[@b83-copd-7-297], indicating moderate quality overall. One of these was an SR without a meta-analysis that evaluated the benefits of AT, RT, BT, and gait on numerous exercise- and disease-related outcomes. It was reported that exercise resulted in improvements in balance measures such as the timed-up-and-go, upper extremity strength, and walking velocity, as well a reduction in fall incidence and fall-related fractures.[@b82-copd-7-297] The other paper included a meta-analysis investigating the benefits of RT with or without balance exercise, and reported that exercise improved several quality-of-life domains including physical function, pain, and vitality.[@b83-copd-7-297]

### Type 2 diabetes mellitus

Seven meta-analyses investigated the benefits of RT and or AT in people with type 2 diabetes with AMSTAR scores that ranged from 6 to 11.[@b84-copd-7-297]--[@b90-copd-7-297] Aerobic exercise improved VO~2~ max as evidenced by two SRs with AMSTAR scores of 6 and 11.[@b84-copd-7-297],[@b89-copd-7-297] Two SRs with AMSTAR scores of 6 also demonstrated reductions in SBP and DBP after AT, RT, or a combination of AT and RT.[@b85-copd-7-297],[@b88-copd-7-297] Strength measures improved after RT, as described by one SR with an AMSTAR of 7.[@b86-copd-7-297] Glycosylated hemoglobin (HbA~1c~), a measure of blood sugar levels, was the most consistent outcome reported in all of the included SRs, with a reduction in this seen in all reviews regardless of the type of exercise training.[@b84-copd-7-297]--[@b90-copd-7-297]

The exercise interventions described were quite varied across the SRs. AT consisted of stationary cycling, outdoor cycling, walking, jogging, swimming, rowing, or skiing. RT was performed using a Theraband, free weights, or weight machines. AT intensity ranged 50%--85% of VO~2~ max, 35%--85% of HRmax, or 40%--80% of HRR. RT intensity ranged 50%--85% of one RM. The exercise sessions were between 30 and 120 minutes, and the duration of the program ranged from 5 to 52 weeks. The SRs primarily focused on the benefits of AT, RT, or a combination of these interventions. However, no studies focused on balance or functional training, or reported functional or quality-of-life outcomes.

### HIV/AIDS

Interval and continuous AT improved VO~2~ max in patients living with HIV, as evidenced by a Cochrane review with an AMSTAR score of 10.[@b91-copd-7-297] This SR also described improved strength in five of the six studies that reported this measure. Additional benefits from exercise training include no change in the viral load, an increase in CD4 cell counts after interval AT, and improved Profile of Moods scores after AT. A summary of the interventions applied is shown in [Table 3](#t3-copd-7-297){ref-type="table"}.

### Depression

The five SRs relating to depression were moderate-to-high quality (AMSTAR 8--11).[@b92-copd-7-297]--[@b96-copd-7-297] Exercise programs (AT, RT, or a combination of these) for people diagnosed with major or minor depression were found to result in improved scores on depression and mood, particularly in the short term.[@b92-copd-7-297],[@b93-copd-7-297] Medium- to long-term effects were less clear.[@b92-copd-7-297],[@b93-copd-7-297] As a group of studies, the interventions were not well described. Most examined both AT, RT, and mixed AT plus RT, except one[@b92-copd-7-297] that focused on AT. The intensity of AT, if described, was moderate to high.[@b93-copd-7-297],[@b95-copd-7-297] Each session was 30 to 60 minutes in length, with these performed one to five times per week, and the duration of the programs was between 10 days and 52 weeks.

Discussion
==========

This synthesis examined 58 systematic reviews of exercise training in people with AECOPD, COPD, or eleven chronic conditions commonly associated with COPD. Overall, this review provides Level 1A evidence[@b97-copd-7-297] that exercise training improves generic or disease-specific measures of fitness in several disease populations. Markers of endurance (aerobic capacity, 6MWD) were shown to improve in all conditions except depression, whereas strength was shown to improve in most conditions with the exception of PVD, hypertension, obesity, and depression. In addition, several studies in different disease populations also reported improvements in quality of life, function, control, or prevention outcomes. Depression was the only condition where SRs exclusively focused on disease-specific outcomes (measures of depression and anxiety).[@b92-copd-7-297]--[@b96-copd-7-297] Exercise training also decreases the risk of mortality in older adults,[@b50-copd-7-297] and in those with COPD[@b39-copd-7-297] or ischemic heart disease.[@b66-copd-7-297]

Overwhelmingly, the most common types of training provided to people with all conditions reviewed were AT and RT. Balance and functional training were less commonly applied SRs of exercise training. However, these interventions had widespread application in most SRs that examined older adults,[@b46-copd-7-297]--[@b49-copd-7-297],[@b51-copd-7-297],[@b52-copd-7-297] and in one SR that examined OA patients[@b79-copd-7-297] and one that examined osteoporosis patients.[@b82-copd-7-297]

The quality of the SRs for most conditions was moderate to excellent (\>65%) as evaluated by AMSTAR scores. However, SRs that examined training outcomes in heart failure, ischemic heart disease, hypertension, and osteoporosis scored moderately poorly on the AMSTAR (≥51% but ≤61%). The listing of articles that were excluded from in the review was the most common item omitted from most SRs, which may have been due to page constraints. Even with this item excluded, the AMSTAR scores remained relatively low for heart failure (56%) whereas scores for the other conditions were ≥66%. In addition to the SR design and strength of AMSTAR scores, the number of participants and RCTs for each condition, including COPD, were large. These numbers further strengthen the foundation of evidence and recommendations for exercise training as an intervention that produces positive outcomes for COPD and commonly associated conditions.[@b98-copd-7-297]

Although COPD patients often have one or more comorbidities, no information is available, on prescription parameters of exercise training for patients with multimorbidity. Training parameters from studies examining conditions that are common comorbidities might be applicable, however, consideration should be give to similarities of patient demographics and details of training, especially intensity. Given that the most common conditions associated with COPD are obesity (prevalence of 54%),[@b26-copd-7-297] osteoporosis (60%--70%)[@b23-copd-7-297] and osteoarthritis (increasing prevalence to 40% at age 75)[@b27-copd-7-297] (see [Table 1](#t1-copd-7-297){ref-type="table"}), data from SRs describing these conditions may have the greatest relevance. The pertinence of these data is further strengthened by the similarity in age of participants from SRs that examined exercise training in people who were obese, had osteoporosis or osteoarthritis to those affected by COPD. In contrast, subjects were somewhat younger in some of the RCTs that examined obesity. Gender was mixed in all of these conditions, except in the case of the SRs on osteoporosis in which predominantly women were studied.[@b82-copd-7-297],[@b83-copd-7-297]

The modalities of AT and RT for obesity, osteoporosis, and osteoarthritis were similar to those typically applied for COPD patients, although exercise training for these conditions utilized more diverse types of training. The intensity of AT appeared to be much higher for obese individuals and those with arthritis compared to that prescribed for COPD patients; intensity was commonly based on aerobic or HR parameters for the former compared to walk distance or dyspnea measures used in COPD patients. This raises the notion that a broader spectrum approach to exercise training in order to improve fitness in patients with COPD and comorbidities such as obesity, osteoporosis, and osteoarthritis may be effective. However, exercise training of the more complex COPD patient (with multiple comorbidities) may result in smaller gains of disease-specific outcomes due to the inability to achieve comparable AT and RT intensities (compared to those achieved in patients with a single condition). These issues merit further study.

Because obesity is a major cause of morbidity and a significant risk factor for other comorbidities such as heart disease and diabetes,[@b26-copd-7-297],[@b75-copd-7-297],[@b76-copd-7-297] SRs addressing exercise fitness outcomes other than body composition are needed in order to determine the overall impact of exercise training in this particular group. Although altering body composition may be the primary outcome for people who are obese, understanding the training and physiologic determinants to achieve that goal are essential; thus fitness outcomes such as aerobic capacity and strength measures should be reported in order to better evaluate the type and intensity of training that results in improvement. Moreover, it has also recently been demonstrated that some obese COPD patients have better fitness outcomes than non-obese COPD patients.[@b99-copd-7-297] Determining how physical activity interventions can attenuate obesity, reduce cardiovascular risk factors, and improve overall fitness in people with COPD needs further attention.

Depression is a common comorbidity in COPD with estimates of prevalence ranging between 10% and 80%.[@b25-copd-7-297] SRs that examined the effect of exercise on depression had participants with an age range similar to those with COPD, and the interventions were similar to many of the other conditions in this review. A major contrast to the other SRs was that only disease-specific outcomes and no generic fitness measures were reported. All five SRs demonstrated significant decreases in depression or anxiety scores.[@b92-copd-7-297]--[@b96-copd-7-297] These benefits were reported regardless of whether AT, RT, or a combination of AT and RT were applied. Of interest is the finding that the benefits decreased in response to longer training programs. More RCTs are needed to examine clinical sub-groups (minor, moderate, major depression), to compare different forms of exercise, and to clarify the appropriate dose/intensity of physical exercise in addition to the mechanism of improvement. Designing a training program that might result in gains related to self-efficacy would be very different from a regimen that requires improved aerobic fitness or an endorphin response to induce a therapeutic benefit. A better understanding of the type of depression most commonly experienced by COPD will also provide further insight into if and how exercise training can reduce the clinical severity of these two conditions.

Exercise training for older adults showed the greatest contrasts to interventions applied to COPD and other associated conditions in this review. This is especially important given that many individuals with COPD who present for health care interventions are 65 or older. Major foci appeared to be on balance and functional training rather than predetermined intensities of AT or RT.[@b46-copd-7-297]--[@b49-copd-7-297],[@b51-copd-7-297],[@b52-copd-7-297] In addition, frequently reported outcomes by the SRs on the elderly included balance/falls, and physical performance measures that were functional (ie, timed up-and-go, stair climbing) as opposed to more physiologic measures of strength and endurance. Exercise training for older adults may provide an excellent model to further broaden exercise prescription for COPD patients because, as with the elderly,[@b48-copd-7-297],[@b49-copd-7-297] people with COPD have a high relative risk of falls.[@b100-copd-7-297] In addition, the physical activity level of COPD patients is often comparable to much older, healthier adults. Thus, a greater focus on balance and functional training may not only reduce falls in COPD patients but might also result in greater gains in daily physical activity outside of pulmonary rehabilitation.[@b101-copd-7-297]

Limitations
===========

Although this synthesis of systematic reviews examined several conditions commonly associated with COPD, the participants within each of the SRs most often had a homogeneous presentation of the condition of interest. Only SRs of the elderly appeared to include participants with diverse and multiple morbidities. For this reason, it might be challenging to apply modalities in a sufficient dose in order to induce both generic and disease-specific benefits that address a complex patient with COPD and multimorbidities. The more functional approach of physical activity training, even in the frail elderly, did result in functional gains, and this approach may also prove to be beneficial to the AECOPD patients with multimorbidities.

Many SRs included lengthy training programs but did not compare the benefits of shorter versus longer programs, with the exception of SRs that evaluated those with hypertension[@b72-copd-7-297],[@b74-copd-7-297] and depression.[@b92-copd-7-297],[@b93-copd-7-297] These SRs indicated a slightly diminished response with longer training programs, which may have resulted in a blunting of the physiologic benefits of exercise, decreased adherence to the exercise training program, or a continued onslaught of inciting factors that could no longer be countered by the benefits of exercise training.

Conclusions
===========

In summary, this systematic review showed evidence of significant benefits from exercise training in AECOPD, COPD, and many conditions that are common comorbidities associated with COPD. Exercise training, primarily consisting of AT and/or RT, leads to meaningful generic and disease-specific benefits in these conditions. Meta-analyses of endurance (aerobic or exercise capacity, 6MWD) were shown to improve in most conditions whereas meta-analyses of strength were shown to improve in five of the 13 conditions (that is, COPD, older adults, heart failure, ischemic heart disease, and diabetes). Additional research is required to determine the added benefit of RT plus AT in several conditions that are common comorbidities associated with COPD.

A broader approach to exercise and activity prescription in pulmonary rehabilitation for AECOPD may induce therapeutic benefits to ameliorate clinical sequelae associated with COPD and comorbidities. For example, BT and functional training, similar to that applied in older adults, could potentially be very effective in improving functional outcomes including fall risk, and may have a greater impact on daily physical activity than recently demonstrated.[@b101-copd-7-297]
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Most of the numbered items are entered as keywords or phrases in the search box on the main page of Medline OvidSP. However, some line items at the end of each concept (eg, line 7) are commands to combine previous items in a particular fashion for the main concept. Asterisks indicate truncated terms in Medline. As well, abbreviations (ie, adj3) can be used to link words together.

Similar search terms were used in all databases. However, the preferred term could differ and the user needed to determine if the alternate term provided in a database was suitable. In addition, the manner of truncation, labeling for title or abstract, and combining of terms differed amongst databases.

Concept: COPD
=============

1.  lung diseases, obstructive/or exp pulmonary disease, chronic obstructive/or bronchitis, chronic/

2.  exp Pulmonary Emphysema/

3.  (obstruct\* adj3 (pulmonary or lung\* or airway\* or airflow\* or bronch\* or respirat\*)).ti,ab.

4.  ((chronic airflow or chronic airway\*) adj2 (disease\* or disorder\* or obstruct\* or limitation\*)).ti,ab.

5.  (COPD or COAD or chronic bronchi\* or emphysema\* or hyperlucent lung\*).ti,ab.

6.  (chronic adj3 obstructive).ti,ab.

7.  or/1--6

Concept: comorbidities
======================

1.  8\. bronchial diseases/or asthma/or bronchial hyperreactivity/or bronchial spasm/or bronchiectasis/or exp bronchitis/or bronchopneumonia/

2.  9\. (bronchial disease\* or asthma\* or bronchial asthma\* or bronchial hyperreactivit\* or bronchospasm\*).ti,ab.

3.  10\. (bronchiectas\* or bronchitis or bronchopneumonia\* or bronchial pneumonia\*).ti,ab.

4.  11\. exp Pneumonia/

5.  12\. (pneumonia\* or pneumoniti\* or pulmonary inflammation\* or lung inflammation\* or lobar pneumonia\*). ti,ab.

6.  13\. Influenza, Human/

7.  14\. ((influenza adj3 human\*) or human flu or influenza\* or grippe).ti,ab.

8.  15\. respiratory insufficiency/

9.  16\. (respiratory insufficiency or respiratory failure or respiratory depression).ti,ab.

10. 17\. heart diseases/or arrhythmias, cardiac/or heart failure/or myocardial ischemia/or myocardial infarction/or pulmonary heart disease/

11. 18\. (arrythmia or arrhythmia or cardiac arrhythmia\* or cardiac dysrhythmia\*).ti,ab.

12. 19\. (heart failure or cardiac failure or myocardial failure or heart decompensation or myocardial infarction).ti,ab.

13. 20\. (pulmonary heart disease\* or cor pulmonale).ti,ab.

14. 21\. Hypertension/

15. 22\. (hypertension or high blood pressure).ti,ab.

16. 23\. Diabetes Mellitus/

17. 24\. (diabetes mellitus or diabetes).ti,ab.

18. 25\. Obesity/or Overweight/

19. 26\. (obesity or overweight).ti,ab.

20. 27\. Sleep Apnea, Obstructive/

21. 28\. (sleep apnea or obstructive sleep apnea or obstructive sleep apnea syndrome).ti,ab.

22. 29\. Depression/

23. 30\. (depression\* or depressive symptoms or emotional depression\*).ti,ab.

24. 31\. Anxiety/

25. 32\. (anxiet\* or nervousness or anxious).ti,ab.

26. 33\. Anemia/

27. 34\. (anemia\* or anaemia).ti,ab.

28. 35\. Osteoporosis/

29. 36\. (osteoporos\#s or senile osteoporos\#s or bone-loss\*). ti,ab.

30. 37\. Osteoarthritis/

31. 38\. (osteoarthritis or osteoarthritides or osteoarthros\#s or degenerative arthritis).ti,ab.

32. 39\. osteopenia.mp.

33. 40\. exp aged/or frail elderly/

34. 41\. (aged or elderly or frail elderly or frail elder\* or frail older adult\*).ti,ab.

35. 42\. or/8--41

36. 43\. 7 or 42

Concept: hospitalized patients
==============================

1.  44\. exp Inpatients/

2.  45\. Hospitalization/

3.  46\. (inpatient\* or in-patient\* or hospitalized or hospitalised or hospitalization\*).ti,ab.

4.  47\. or/44--46

5.  48\. 43 and 47

Concept: exercise
=================

1.  49\. exp exercise/or exp walking/

2.  50\. exp Exercise Therapy/

3.  51\. Physical Fitness/

4.  52\. Exercise Movement Techniques/

5.  53\. (exercise\* or physical exercise\* or exercise therap\* or walk\* or ambulat\* or physical fitness or physical activity). ti,ab.

6.  54\. (exercise\* adj5 train\*).mp.

7.  55\. (strength\* adj5 train\*).mp.

8.  56\. exp "Physical Therapy (Specialty)"/

9.  57\. (physiother\* or physical therap\*).mp.

10. 58\. Rehabilitation/

11. 59\. rehabilitat\*.mp.

12. 60\. or/49--59

13. 61\. 48 and 60

14. 62\. animals/not humans/

15. 63\. 61 not 62

16. 64\. limit 63 to English

![Flow chart of retrieval, screening and inclusion of systematic reviews.](copd-7-297f1){#f1-copd-7-297}

###### 

Prevalence of chronic diseases in the population and in people with COPD

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chronic disease               Prevalence in population                                                          Prevalence in COPD
  ----------------------------- --------------------------------------------------------------------------------- ---------------------------------------------------------------
  Heart failure                 \<1% age 50--59; \~7% age 80--89[@b22-copd-7-297]                                 20%[@b24-copd-7-297]

  Ischemic heart disease        5%                                                                                Severe and very severe COPD two-fold risk[@b25-copd-7-297]

  Peripheral arterial disease   4.3% at age 40, 14.5% at age 70[@b20-copd-7-297]                                  Smokers OR 4.46[@b20-copd-7-297]

  Hypertension                  15%; \~50% ≥50 years[@b18-copd-7-297]                                             1.6-fold risk[@b25-copd-7-297]

  Obesity                       67% over age 30[@b14-copd-7-297]                                                  54%[@b26-copd-7-297]

  OA                            13% at age 50; \~40% at age 75[@b23-copd-7-297]                                   

  Osteoporosis/osteopenia       15% over age 50[@b21-copd-7-297]                                                  60%--70%[@b27-copd-7-297]

  Diabetes mellitus -- type 2   2.8% in 2000; 6.4% in 2010 with a 10.2% in the Western Pacific[@b16-copd-7-297]   Increased relative risk 1.5--1.8[@b25-copd-7-297]

  Depression                    4.7% persistent depression or anxiety[@b17-copd-7-297]                            Depressive symptoms: 10%--80%[@b25-copd-7-297]\
                                                                                                                  Depression that requires treatment: 19%--42%[@b25-copd-7-297]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

AMSTAR score

  Condition                                     Author                                 AMSTAR scores                                                      
  --------------------------------------------- -------------------------------------- --------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----- ----
  AECOPD                                        Puhan et al[@b39-copd-7-297]           1               1    1    1    1    1    1    1    1    1    1     11
  Chronic obstructive pulmonary disease         Lacasse et al[@b42-copd-7-297]         1               1    1    1    1    1    1    1    1    0    1     10
  O'Shea et al[@b43-copd-7-297]                 1                                      1               1    0    0    1    1    1    1    0    1    8     
  Salman et al[@b44-copd-7-297]                 1                                      0               1    1    0    1    1    1    1    1    0    8     
  Chavannes et al[@b40-copd-7-297]              1                                      0               1    1    0    1    0    0    1    0    0    5     
  Vieira et al[@b45-copd-7-297]                 1                                      0               1    1    0    1    1    1    0    0    0    6     
  Janaudis-Ferreira et al[@b41-copd-7-297]      1                                      0               1    1    0    1    1    0    0    0    0    5     
  Older adults                                  Liu and Latham[@b50-copd-7-297]        1               1    1    1    1    1    1    1    1    1    1     11
  Howe et al[@b49-copd-7-297]                   1                                      1               1    1    1    1    1    1    1    0    1    10    
  Gillespie et al[@b48-copd-7-297]              1                                      1               1    1    1    1    1    1    1    1    1    11    
  Weening-Dijksterhuis et al[@b52-copd-7-297]   1                                      0               1    1    0    1    1    1    0    1    1    8     
  Forster et al[@b47-copd-7-297]                1                                      1               1    1    0    0    0    0    0    0    1    5     
  Chin et al[@b46-copd-7-297]                   1                                      1               1    1    0    1    1    1    0    0    1    8     
  Rydwik et al[@b51-copd-7-297]                 1                                      0               1    1    0    1    1    1    0    0    0    6     
  Heart failure                                 Davies et al[@b55-copd-7-297]          1               0    1    0    0    0    1    1    1    1    1     7
  Hwang et al[@b54-copd-7-297]                  1                                      1               1    0    0    1    1    1    1    1    0    8     
  Hwang and Marwick[@b57-copd-7-297]            1                                      0               1    0    0    1    0    0    0    0    0    3     
  Chien et al[@b53-copd-7-297]                  1                                      1               1    1    0    1    1    0    1    0    0    7     
  Haykowsky et al[@b56-copd-7-297]              1                                      1               1    1    0    1    1    1    0    1    0    8     
  van Tol et al[@b58-copd-7-297]                1                                      1               1    0    0    0    1    1    1    1    0    7     
  Spruit et al[@b61-copd-7-297]                 1                                      1               1    0    0    1    1    1    0    0    0    6     
  Cahalin et al[@b60-copd-7-297]                1                                      0               0    0    0    1    0    0    0    0    0    2     
  Benton[@b59-copd-7-297]                       1                                      0               0    0    0    1    0    0    0    0    0    2     
  Ischemic heart disease                        Haykowsky et al[@b65-copd-7-297]       1               1    1    0    0    1    1    1    1    0    1     8
  Valkeinen et al[@b68-copd-7-297]              1                                      0               0    0    0    1    1    0    1    1    0    5     
  Cortes et al[@b64-copd-7-297]                 1                                      1               1    1    0    1    1    1    1    0    1    9     
  Jolliffe et al[@b66-copd-7-297]               1                                      1               1    0    1    1    1    1    1    1    1    10    
  Clark et al[@b62-copd-7-297]                  1                                      1               1    0    0    1    1    1    1    1    1    9     
  Cornish et al[@b63-copd-7-297]                1                                      0               1    0    0    1    0    0    0    0    0    3     
  Oliveira et al[@b67-copd-7-297]               1                                      0               1    0    0    1    0    0    0    0    0    3     
  PVD                                           Watson et al[@b69-copd-7-297]          1               1    1    0    1    1    1    1    1    0    1     9
  Wind and Koelemay[@b70-copd-7-297]            1                                      1               1    0    0    0    1    1    1    1    0    7     
  Hypertension                                  Dickinson et al[@b73-copd-7-297]       1               1    1    0    1    0    1    1    1    1    0     8
  Cornelissen and Fagard[@b72-copd-7-297]       1                                      1               0    0    0    0    0    0    1    1    0    4     
  Whelton et al[@b74-copd-7-297]                1                                      1               1    0    1    1    0    0    1    1    1    8     
  Kelley et al[@b71-copd-7-297]                 1                                      1               1    1    0    0    1    0    1    1    0    7     
  Obesity                                       Shaw et al[@b76-copd-7-297]            1               1    1    1    1    1    1    1    1    1    1     11
  Witham and Avenell[@b75-copd-7-297]           1                                      1               1    0    0    1    1    0    1    1    1    8     
  Osteoarthritis                                Devos-Comby et al[@b79-copd-7-297]     1               0    1    1    0    1    1    1    1    1    0     8
  Lange et al[@b80-copd-7-297]                  1                                      1               1    0    0    1    1    1    1    0    0    7     
  Ottawa Panel[@b77-copd-7-297]                 1                                      1               1    1    1    1    1    1    0    0    0    8     
  Brosseau et al[@b78-copd-7-297]               1                                      1               1    1    0    1    1    1    0    0    0    7     
  Pelland et al[@b81-copd-7-297]                1                                      1               1    1    1    1    1    1    1    0    0    9     
  Osteoporosis                                  Li et al[@b83-copd-7-297]              1               0    1    0    0    0    1    1    1    0    1     6
  de Kam et al[@b82-copd-7-297]                 1                                      0               1    1    0    1    1    1    0    0    1    7     
  Diabetes mellitus                             Chudyk and Petrella[@b85-copd-7-297]   1               0    1    1    0    1    0    0    1    0    1     6
  Umpierre et al[@b90-copd-7-297]               1                                      1               1    1    0    1    1    1    1    1    1    10    
  Irvine and Taylor[@b86-copd-7-297]            1                                      1               1    0    0    1    1    1    1    0    0    7     
  Thomas et al[@b89-copd-7-297]                 1                                      1               1    1    1    1    1    1    1    1    1    11    
  Kelley and Kelley[@b87-copd-7-297]            1                                      1               1    1    0    1    1    1    1    1    0    9     
  Snowling and Hopkins[@b88-copd-7-297]         1                                      0               1    0    0    1    1    1    1    0    0    6     
  Boulé et al [@b84-copd-7-297]                 1                                      0               1    1    0    1    1    0    1    0    0    6     
  HIV                                           O'Brien et al[@b91-copd-7-297]         1               1    1    1    1    1    1    1    1    0    1     10
  Depression                                    Krogh et al[@b93-copd-7-297]           1               1    1    1    0    1    1    1    1    1    1     10
  Herring et al[@b94-copd-7-297]                1                                      0               1    1    0    0    1    1    1    1    1    8     
  Mead et al[@b96-copd-7-297]                   1                                      1               1    1    1    1    1    1    1    1    1    11    
  Rethorst et al[@b95-copd-7-297]               1                                      1               1    1    0    1    1    0    1    0    1    8     
  Lawlor and Hopker[@b92-copd-7-297]            1                                      1               1    1    0    1    1    1    1    0    1    9     
  Tallies for 58 reports                        58                                     38              54   34   15   49   48   41   42   26   29   434   
  Percentage of total (58 reports)              100                                    66              93   59   26   84   83   71   72   45   50         

###### 

Characteristics of participants and interventions

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                         RCTs                   n (% M or F)                                Age (years)               Characteristics of exercise intervention
  ---------------------------------------------- ---------------------- ------------------------------------------- ------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **AECOPD**                                                                                                                                  

  Puhan et al[@b39-copd-7-297]                   9                      427 (64% M)                                 Range 62--70              **Mo**: AT and RT; **Fr**: Twice daily -- 3×/week; **T**: NR except one study stated 2 hours/session; **D**: 10 days--6 months

  **COPD**                                                                                                                                    

  Lacasse et al[@b42-copd-7-297]                 31                     1322                                        NR                        **Mo:** AT and RT, U/E, L/E, and/or respiratory muscle training; **Fr** and **I**: NR; **D**: 4--52 weeks

  O'Shea et al[@b43-copd-7-297]                  9 of 18                296 of 679 (70% M)                          Range 48.5--72            **Mo**: RT using free weights, machine, Theraband; **Fr**: 2×/week--daily; **I**: variable; **T**: 5--12 reps, 2--4 sets; **D**: 6--12 weeks

  Salman et al[@b44-copd-7-297]                  20                     999                                         59--73                    **Mo**: AT, RT: U/E, L/E, and/or respiratory muscle training; **Fr**: ≥3 ×/week; **D**: 6 weeks--12 months; other details NR

  Chavannes et al[@b40-copd-7-297]               4 of 5                 210 (\~55% M)                               49--63                    **Mo**: AT + RT (four studies), AT (one study); **Fr**: 2--7×/week; **D**: 8 weeks--18 months; other details NR

  Vieira et al[@b45-copd-7-297]                  8 of 12                370 of 728                                  Range 38--78              **Mo**: Home-based AT and RT; **Fr**: 2×/week -- twice daily; **I**: 90% of velocity of 6 MWD, ≥70% of maximal speed of SWT, cycle ergometer: 30 W, cycling: 70% of work rate; **T**: 30--60 minutes; **D**: 4--52 weeks

  Janaudis-Ferreira et al[@b41-copd-7-297]       5                      157                                         NR                        **Mo**: Arm AT and RT; **Fr**: 3×/week -- 2×/day; **I**: NR; **T**: 4--10 reps 1--3 sets; **D**: 6--8 weeks

  **Older adults**                                                                                                                            

  Liu and Latham[@b50-copd-7-297]                83 of 121              3059 of 6700                                \>60                      **Mo**: RT in gym or against Theraband; **Fr**: 2--3×/week, except one was daily; **I**: ranged from low to high intensity; **D**: most 8--12 weeks but ranged from 2--104 weeks

  Howe et al[@b49-copd-7-297]                    34                     2883 (\<50% M)                              60--75 years              **Mo**: RT, gait, balance, co-ordination, and functional tasks, tai chi, qi gong, dance, yoga; other details NR

  Gillespie et al[@b48-copd-7-297]               14 of 111              55303 (\<50% M)                             \>60                      **Mo**: AT, RT, gait, balance and functional training, flexibility training, tai chi, and square stepping; general physical activity (walking groups); other details NR

  Weening- Dijksterhuis et al[@b52-copd-7-297]   27                     6459                                        \>70                      **Mo**: RT (strength, resistance), ROM, balance, functional, gait, tai chi, flexibility; other details NR

  Forster et al[@b47-copd-7-297]                 37 of 49               3611 (33% M)                                Mean 82                   **Mo**: RT, AT (walking) and general daily living skills eg, eating, dressing, and climbing stairs, flexibility, balance; **Fr**: mean of 3.5×/week **T**: ≤30 minutes/week; **D**: 4 weeks--2 years

  Chin et al[@b46-copd-7-297]                    20                     2515 (majority F)                           77--88                    **Mo**: AT, RT, flexibility, balance, tai chi, and/or multi-component training; **Fr**: usually 3×/week; **D**: range 10--28 weeks

  Rydwik et al[@b51-copd-7-297]                  16                     1269                                        \>70                      **Mo**: RT, gait, and ROM training; **Fr**: usually 2--3×/week **T**: variable; **D**: 9 weeks--2 years

  **Heart failure**                                                                                                                           

  Davies et al[@b55-copd-7-297]                  19                     3647 (majority M)                           51--72                    **Mo**: AT or AT + RT; **Fr**: 2--7×/week; **I:** 40% max HR or 85% VO~2~ max; **T**: 15--120 minutes; **D**: 24 weeks--3 years

  Hwang et al[@b54-copd-7-297]                   4 of 8                 103 (60% M)                                 62--77                    **Mo**: RT for U/E and L/E; **Fr**: 2--3×/week; **I**: 60%--80% 1RM; **T**: 12--60 minutes; **D**: 8--22 weeks

  Hwang and Marwick[@b57-copd-7-297]             19                     1069 (85% M)                                59.05 (95% CI 55--63)     **Mo:** AT or AT + RT: cycle ergometer, walking, calisthenics, ball games, strength training; **Fr:** NR; **I:** AT: −10% of AT, 60%--80% HRmax, 70% VO~2~ max RT: 80% 1RM, 70% HRmax; **T:** 40--400 minutes/week; **D:** 8--52 weeks

  Chien et al[@b53-copd-7-297]                   10                     648 (79% M)                                 52--81                    **Mo**: Home based AT (walking program, and/or cycle ergometer) and RT (added in 3/10 studies); **Fr**: 2--5×/week; **I**: 40%--70% HRmax, or 70% HR at VO~2~ max; **T**: 20--60 minutes; **D**: 6--52 weeks. All home programs

  Haykowsky et al[@b56-copd-7-297]               9 of 14                538 of 812 (83% M)                          52--61                    **Mo:** AT: cycle ergometer, rowing, swimming, walking, arm ergometer, treadmill, interval training; **Fr:** 2--7 days/week; **I:** 50%--80% VO~2~ peak, 60%--85% HRpeak, or 50%--70% max work load; **T:** 20--60 minutes; **D:** 2--14 months

  van Tol et al[@b58-copd-7-297]                 35                     1486 (76% M)                                Mean 60.6 (SD 7.5)        **Mo**: AT + RT; **Fr**: range 1--7×/week, mean 3.7×/week; **I**: 50%--80% VO~2~ peak, 60%--80% HRmax, 60%--80% HRR; **T**: 15--96 minutes, 50 minutes (mean); **D**: 3--26 weeks, 13.0 weeks (mean)

  Spruit et al[@b61-copd-7-297]                  4 of 10                114 (72% M)                                 Mean 57--77               **Mo:** RT alone **Fr:** 2--3×/week; **I:** 40%--80% 1 RM; **T:** 15--60 reps in 1--3 sets; **D:** 8--20 weeks; progression described in some reports

  Cahalin et al[@b60-copd-7-297]                 11 of 22               387 of 633 (70% M)                          30--80                    **Mo**: RT: variety of strength exercises either alone or with short or long bursts of AT; **Fr**: 2--5×/week; **I**: RT: 20%--80% 1RM; AT: up to 80% VO~2~ peak, or 70% HRpeak, or 50% peak workload; **T**: 5--60 minutes; **D**: 4--26 weeks

  Benton[@b59-copd-7-297]                        4 of 16                115 of 379 (80% M)                          Mean 30--76               **Mo**: RT: chair stands, heel lifts, weights, pulleys, hydraulic fitness; **Fr**: 2--3×/week, **I:** 60% 1 RM; AT: cycling, arm ergometer, stair climbing, walking; **T**: 2--60 minutes; **D**: 2--5 month study duration; reps and progression: variable

  **Ischemic heart disease**                                                                                                                  

  Haykowsky et al[@b65-copd-7-297]               12                     647                                         55                        **Mo**: AT: Cycle, walk, jogging, calisthenics; **Fr**: 3--7×/week; **I**: 60%--80% VO~2~ max or peak HR; **T**: 30--180 minutes; **D**: 1--6 months

  Valkeinen et al[@b68-copd-7-297]               18                     922 (majority M)                            59.9 ± 4.9                **Mo**: AT: walking, jogging, cycling, and arm cranking; **Fr**: 3.1 ± 0.4×/week; **I**: 70%--80% HRmax, HRR, HR of anaerobic threshold or 25%--70% VO~2~ max; **T**: 20--60 minutes; **D:** 14.2 ± 13.5 weeks **Mo**: RT: **Fr**: 3.5 ± 0.7×/week; **I**: 50%--80% 1 RM or 40%--60% MVC; **T**: 20--60 minutes**; D**: 22.0 ± 11.1 weeks

  Cortes et al[@b64-copd-7-297]                  11 of 14               3148 (≥70% M)                               55--65                    **Mo:** Early mobilization: sitting on bed/chair, walking, moving legs, climbing stairs, any movement out of bed, dangling legs, progressive activity while in hospital; settings descriptions: CCU, hospital wards, in-hospital

  Jolliffe et al[@b66-copd-7-297]                32                     8440 (majority M)                           55                        **Mo:** AT: walking, running, cycling, skipping, swimming, stairs, and rowing; **Fr**: 1--5×/week; **I:** 70%--85% HRmax or predicted HRmax, other 75% max work capacity; **T**: 20--60 minutes; **D**: 4 weeks to 30 months **Mo:** RT: strengthening exercises for U/E and L/E; **Fr:** 3×/week; **I:** Target HR 85% HRmax; **T:** 60 minutes; **D:** 12 weeks

  Clark et al[@b62-copd-7-297]                   41 of 63               8460 of 21295 (majority M)                  Mean 49--71               AT, RT: no details on intervention

  Cornish et al[@b63-copd-7-297]                 2 of 7                 120 of 213                                  57 ± 14--71.5 ± 7.8       **Mo**: AT: interval training: aerobic dance movements, upper/lower body exercises, cycle ergometer, or treadmill walking/running; **Fr**: 2--3×/week; **I**: 3 intervals of 5--10 minutes at RPE 15--18 in one study and 3 minutes at 60%--70% HRmax + 4 minutes at 90%--95% HRmax in another; **T**: 50--60 minutes; **D**: 16--26 weeks

  Oliveira et al[@b67-copd-7-297]                4 of 11                126                                         most \<60                 **Mo**: RT: free weights in one study, NR in others; **I**: 40%--60% MVC or 50%--80% 1 RM**; D**: 10 weeks to 6 months; Other details NR

  **PVD**                                                                                                                                     

  Watson et al[@b69-copd-7-297]                  16 of 22               783 of 1200 (\>50% M)                       45--89                    **Mo**: AT, RT: polestriding, cycling, and U/E and L/E exercises. **Fr**: 2--7×/week; **T**: 30--120 minutes; **D**: 3--12 months

  Wind and Koelemay[@b70-copd-7-297]             10 of 15               625 of 761 (\>50% M)                        60--76                    **Mo**: AT: crank exercise, walking, others not detailed. **Fr**: 2--3×/week; **T**: 30--60 minutes; **D**: 12--26 week except one study was 104 weeks

  **Hypertension**                                                                                                                            

  Dickinson et al[@b73-copd-7-297]               21 of 105              1518 of 6805 (\~57% M)                      52 (30--67)               **Mo**: AT: brisk walking, jogging, cycling; **Fr**: 3--5×/week; **T**: 30--60 minutes; **D**: 8--52 week (median 12). 2 trials received RT, but details NR; 1 trial offered advice to participants

  Cornelissen and Fagard[@b72-copd-7-297]        28 of 72               492 in exercise group                       52.7 ± 11.8               **Mo:** AT: walking, jogging, running, cycling; **Fr**: 2--7×/week (median 3); **I**: 30%--87% HRR (median 65); **T**: 25--60 minutes (median 40); **D**: 4--52 weeks (median 12)

  Whelton et al[@b74-copd-7-297]                 15 of 54               872 (majority M)                            Mean 40--69\              **Mo**: AT: biking, walking, jogging; **Fr**: 1--7×/week; **I**: 40%--70% VO~2~ max, 60%--85% HRmax, 40%--70% Wmax; **T**: 20--60 minutes; **D**: 3--26 weeks
                                                                                                                    Range 18--86              

  Kelley et al[@b71-copd-7-297]                  47                     2543\                                       48                        **Mo:** AT: walking, jogging, cycling, aerobic dance, and swimming; **Fr:** 1--5×/week; **I**: 45%--86% VO~2~ max; **T:** 15--60 minutes; **D:** 360--9360 minutes
                                                                        \>50% M                                                               

  **Obesity**                                                                                                                                 

  Shaw et al[@b76-copd-7-297]                    4 of 41                440 of 3476 (majority M)                    30--64                    **Mo**: AT: walking/jogging, circuit training; **Fr**: 2--3×/week; **I**: 60%--80% HRmax; **T**: 30--60 minutes; **D**: 26--52 weeks

  Witham and Avenell[@b75-copd-7-297]            2 of 9                 173 (100% F)                                60                        **Mo:** supervised AT, no details; **Fr:** 3×/week; **I:** aiming for 70% VO~2~ max; **T**: NR; **D:** 3 months; Transition to home: exercise 4×/week plus weekly supervised exercise

  **OA**                                                                                                                                      

  Devos-Comby et al[@b79-copd-7-297]             16                     2154                                        Mean 65.8, range 29--89   **Mo**: AT + RT: knee muscles strength training, low/medium intensity exercise, and light physical activity (walking, aerobic exercise, balance or flexibility exercises); **Fr:** 2--5×/week (sometimes 2×/day); **I:** AT: 50%--85% HRR, RT: 6 set × 5 max contraction (others NR); **T**: 20 minutes -- 1.5 hour; **D**: 4--12 weeks (different follow-up periods)

  Lange et al[@b80-copd-7-297]                   18                     2723                                        Range 55--74              **Mo**: RT: dynamic or isotonic training mainly targeting the quadriceps using resistance machines, free weights, or Theraband; **Fr**: 2--7×/week; **I**: light to maximal; **T**: 10--60 minutes, 5--12 reps, 1--10 sets (most 3 sets); **D**: 1--30 months

  Ottawa Panel[@b77-copd-7-297]                  26                     2486                                        \>18                      **Mo**: AT: walking or cycle ergometer; RT: strengthening (eg, isometric, isotonic, isokinetic, eccentric, concentric, aerobic), general physical activity, combination of exercises; **Fr**: 1×/week--10×/day (depends on phase); **I:** AT: 50%--70% HRR when described, RT: variable. **T**: 5 minutes--1.5 hours; **D**: 4 weeks--18 months

  Brosseau et al[@b78-copd-7-297]                9 of 12                1363                                        57--69.4                  **Mo:** AT: walking, stationary bike; **Fr:** 1--4 ×/week; **I:** 50%--85% HRR or 60%--80% HRmax. **T:** 30--90 minutes when reported; **D:** 5--12 weeks. Some changed to home-based program up to 15 months. Some studies included strengthening exercises

  Pelland et al[@b81-copd-7-297]                 17 (plus 4 CCTs)       2325                                        Range 55.0--74.6          **Mo**: ROM exercises, low intensity walking on treadmill, RT: quadriceps, hamstrings, and hip abduction strengthening, stationary bike; **Fr**: most 2--3×/week, range: 1×/week--2×/day; **I**: variable; **T**: 15--40 minutes, 3--9 exercises, 6--20 reps, 1--4 sets; **D**: 4 week--15 months

  **Osteoporosis**                                                                                                                            

  Li et al[@b83-copd-7-297]                      5 groups in 4 papers   256 (100% F)                                NR                        **Mo:** RT or combined stretch/strength/balance programs: strengthening of extremities and trunk (1 study), "agility" training (1 study), combined exercise (stretching, strengthening, balance, posture) (2 studies), trunk flexor/extensor strengthening (1 study); **Fr:** 3 studies 2 days/week, 1 study 7 days/week; **I**: NR; **T:** 40--60 minutes; **D:** 10--25 weeks

  De Kam et al[@b82-copd-7-297]                  28                     1707, some reports used the same subjects   Mean 57--82               **Mo:** fast walking; aerobic exercise; weight-bearing aerobic exercise; strengthening exercises; balance exercises; posture and gait exercises; trunk extensor exercises; heel drops with impact; heel drops with no impact; whole body vibration; jumping; agility training including ball games, relay races and obstacle courses; tai chi; home-based walking, strengthening and stretching; **Fr:** 3--7×/week**; I:** not described -- only one study described progression by increasing step count by 30%; **T:** 4--90 minutes; **D:** 10--104 weeks

  **Diabetes**                                                                                                                                

  Chudyk and Petrella[@b85-copd-7-297]           30 of 34               NR                                          NR                        **Mo**: AT; **Fr**: most 3×/week but range of 1--7×/week; **I**: 50%--85% VO~2~ max or 35%--85% HRmax; **T**: 40--75 minutes; **D**: 2--24 months. RT: variable

  Umpierre et al[@b90-copd-7-297]                23 of 47               1513 of 8538                                Range of means 52--69     **Mo**: AT, RT; **Fr**: 2--5×/week **T**: AT: 30--150 minutes/week and RT: 9--27 sets; **D**: 12--52 weeks

  Irvine and Taylor[@b86-copd-7-297]             7 of 9                 162 of 256                                  47--68                    **Mo**: RT: free weights or weight machines; **Fr**: 2--3×/week; **I**: 55%--85% 1RM or to moderate on Borg; **T**: 8--15 reps, 1--3 sets, 5--10 exercises; **D**: 8--26 weeks

  Thomas et al[@b89-copd-7-297]                  14                     377                                         45--65                    **Mo**: qi gong, RT, AT: cycle ergometer, walking cycling, skiing, swimming; **Fr**: 3--7×/week; **I**: AT: 50%--85% VO~2~ peak, 65%--75% HRR or 85% HRmax; **T**: 30--120 minutes; if PRT, 2--3 sets of 10--12 reps; **D**: 8 weeks--1 year

  Kelley and Kelley[@b87-copd-7-297]             7                      Both                                        40--75                    **Mo**: AT: cycle ergometer, walking, jogging, cycling, swimming, skiing; **Fr**: 3--7×/week **I**: 60%--75% VO~2~ max; **T**: 30--75 minutes; **D**: 10--26 weeks

  Snowling and Hopkins[@b88-copd-7-297]          27                     1003                                        55 ± 7                    **Mo**: AT; **Fr**: 3--7×/week; **I**: 50%--85% VO~2~ max, HR 110--140 bpm, 40%--80% HRR; **T**: 30--120 minutes; **D**: 6--104 weeks.\
                                                                                                                                              **Mo**: RT; **Fr**: 3--5×/week; **I**: 50%--80% of 1 RM; **T**: 10--20 reps, 2--3 sets, 5--10 ex; **D**: 5--16 weeks

  Boulé et al[@b84-copd-7-297]                   27                     266                                         55.7                      **Mo**: AT: continuous aerobic; walking, cycling, skiing jogging, rowing, Theraband; **Fr**: 3--6×/week; 60%--75%; **I**: VO~2~ max; **T**: 40--60 minutes; **D**: 8--52 weeks

  **HIV**                                                                                                                                     

  O'Brien et al[@b91-copd-7-297]                 7 of 14                306 of 454 (\~70% M)                        18--58                    **Mo**: AT: interval or continuous aerobic, walking, jogging, stair stepping, ski machine, stationary bike, cross country machine. **Fr**: 3×/week **I**: AT: usually 50%--85% VO~2~ max and 60%--80% HRmax or RT: 60%--80% 1 RM; **T**: 20--60 minutes, **D**: 5--24 weeks

  **Depression/anxiety**                                                                                                                      

  Krogh et al[@b93-copd-7-297]                   13                     272                                         17--85                    **Mo**: AT, RT, AT + RT; **Fr**: 2--5×/week; **D**: 8--16 week; AT: **I**: 70%--80% HRmax, 50%--70% aerobic capacity; **T**: 30--60 minutes. RT: **I**: 80% RM; **T**: 20 minutes or 8 reps × 3 sets

  Herring et al[@b94-copd-7-297]                 40                     NR (59% F)                                  50 ± 10                   **Mo:** AT, RT, AT+RT; **Fr**: 3 ± 1×/wk; **I**: variable; **T**: 42 ± 22; **D**: 16 ± 10 wk

  Mead et al[@b96-copd-7-297]                    23 of 25               640                                         ≥18                       **Mo**: AT: running, treadmill walking or walking, stationary cycling; RT; Mixed: A + RT, qi gong exercises, individually tailored, tai chi; **D**: 10 days -- 16 weeks

  Rethorst et al[@b95-copd-7-297]                58                     2982                                        15--94                    **Mo**: AT; **Fr**: 3--5×/week; **I**: moderate to high **T**: 20--60 minutes; **Mo**: RT; **F**: 2--3 ×/week **T**: 20--60 minutes; **Mo**: A + RT; **T**: 20--90 minutes; **D**: acute -- 52 week

  Lawlor and Hopker[@b92-copd-7-297]             11 of 14               479 (\~34% M)                               All ages                  **Mo**: AT: running, walking; **Fr**: 2--5×/week; **T**: 20--60 minutes; **D**: 4--12 week
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** In RCT columns, number of RCTs from total number of studies. In number of subject's (n) columns, number of subjects that were analyzed and total number of participants.

**Abbreviations:** AECOPD, acute exacerbation of COPD; AT, aerobic training; D, duration of training program; Fr, frequency; HRR, heart rate reserve; I, intensity; L/E: Lower extremity; M, male; F, female; Mo, modality; mod, moderate; NR, not reported; RT, resistance training; T, session time; U/E, upper extremity; ROM, range of motion; SWT, shuttle walking test; PRT, progressive resistance training.

###### 

Generic and disease-specific outcomes from exercise interventions

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                        Condition and severity                                                                    Type of training:                                  Generic fitness, quality of life and functional outcomes \# RCTs/*n*/difference \[95% confidence intervals\]                                                                                                                                                                                                                                              Disease specific fitness, control and prevention outcomes \# trials/*n*/difference \[95% confidence intervals\]
  --------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Puhan et al[@b39-copd-7-297]                  COPD after AECOPD                                                                         AT, RT                                             *6MWD*: 6/NR/WMD: 77.7 m \[12.2, 143.2\];\                                                                                                                                                                                                                                                                                                                *Dyspnea*: 5/NR/0.97 \[0.35, 1.58\];\
                                                                                                                                                                                             *Shuttle walk test*: 3/NR/WMD: 64.4 M \[41.3, 87.4\];\                                                                                                                                                                                                                                                                                                    *Admission to hospital*: 5/250/OR: 0.22 \[0.08, 0.58\];\
                                                                                                                                                                                             *QoL: SGRQ*: 3/NR/WMD: 9.88 \[−14.40, −5.37\]                                                                                                                                                                                                                                                                                                             *Mortality*: 3/110/OR: 0.28 \[0.10, 0.84\]

  Lacasse et al[@b42-copd-7-297]                COPD                                                                                      AT, RT                                             *Maximal exercise capacity on cycle ergometer*: 13/511/WMD: 8.4 watts \[3.45, 13.41\];\                                                                                                                                                                                                                                                                   *QoL*: Change in dyspnea of CRQ: 11/618/WMD: 1.06 \[0.85, 1.26\]
                                                                                                                                                                                             *6MWD*: 16/669/WMD: 48.5 m \[31.6, 65.3\];\                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                             *QoL: Fatigue of CRQ*: 11/618/WMD: 0.92 \[0.71, 1.13\]                                                                                                                                                                                                                                                                                                    

  O' Shea et al[@b43-copd-7-297]                Mild to severe COPD                                                                       RT                                                 *Leg press strength*: 4/77/SES: 0.96 \[0.26, 1.66\];\                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                             *Knee extensor strength*: 3/125/SES: 0.52 \[0.30,0.74\];\                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                             *Cycling endurance*: 2/52/SES: 0.87 \[0.29, 1.44\].                                                                                                                                                                                                                                                                                                       

  Salman et al[@b44-copd-7-297]                 Mild to severe COPD                                                                       AT, RT                                             *Walking distance*: 20/979/SES: 0.71 \[0.43, 0.99\]                                                                                                                                                                                                                                                                                                       *Shortness of breath*: 12/723/SES: 0.62 \[0.26, 0.91\]

  Chavannes et al[@b40-copd-7-297]              Mild to mod. COPD                                                                         AT, AT + RT,                                       *Exercise tolerance*: Limited evidence of improvement. SES NR                                                                                                                                                                                                                                                                                             

  Vieira et al[@b45-copd-7-297]                 COPD                                                                                      Home based AT, RT                                  *Exercise capacity*: 2 of 2 studies show ↑ in 6MWD or constant work rate test;\                                                                                                                                                                                                                                                                           
                                                                                                                                                                                             *QoL*: 3 of 6 studies showed ↑ compared to control                                                                                                                                                                                                                                                                                                        

  Janaudis-Ferreira et al[@b41-copd-7-297]      Mod. to severe COPD                                                                       Arm AT, RT                                         *Unsupported and supported arm exercise capacity*: 2 (of 4) studies and 1 (of 2) showed ↑ compared to control                                                                                                                                                                                                                                             

  Liu and Latham[@b50-copd-7-297]               Elderly                                                                                   RT                                                 *Lower limb strength*: 73/3059/SES 0.84 \[0.67, 1.00\];\                                                                                                                                                                                                                                                                                                  *Death*: 13/1125/RR 0.89 \[0.52, 1.54\];\
                                                                                                                                                                                             *VO~2~* *max*: 18/710/WMD 1.50 mL/kg/min \[0.49, 2.51\];\                                                                                                                                                                                                                                                                                                 *Pain*: 6/503/SES −0.30 \[−0.48, −0.13\]
                                                                                                                                                                                             *6MWD*: 11/325/WMD 52.37 m \[17.38, 87.37\];\                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                             *Gait speed*: 24/1179/WMD 0.08 m/s \[0.04, 0.12\];\                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                             *Timed up-and-go*: 12/691/WMD −0.69 s \[−1.11, −0.27\];\                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                             *Time to stand from a chair*: 11/384/SES −0.94 \[−1.49, −0.38\];\                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                             *Stair climbing*: 8/268/−1.44 s \[−2.51, −0.37\];\                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                             *Vitality: (SF-36)* 10/611/WMD 1.33 \[−0.89, 3.55\];\                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                             *Main function:* 33/2172/SES 0.14 \[0.05, 0.22\]                                                                                                                                                                                                                                                                                                          

  Howe et al[@b49-copd-7-297]                   Improving balance                                                                         Balance, gait, functional task                     *Single leg stance time, eyes open:* 4/164/MD 0.33 s \[0.02, 0.64\];\                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                             *Berg Balance Scale* 3/126/MD 2.72 \[0.94, 4.50\]                                                                                                                                                                                                                                                                                                         

  Gillespie et al[@b48-copd-7-297]              Falls prevention                                                                          Balance, gait, functional                                                                                                                                                                                                                                                                                                                                                                                    *Rate of falls:* 3/461/RR: 0.73 \[0.54, 0.98\] 0.036;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *Number of fallers:* 17/2492/RR: 0.83 \[0.72, 0.97\] 0.018

  Weening-Dijksterhuis et al[@b52-copd-7-297]   Institutionalized frail elderly                                                           AT, RT, balance and functional training            *Strength*: ↑ in 8 of 9 studies;\                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                             *6MWD*: ↑ in 3 of 3 studies;\                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                             *Balance*: ↑ in 10 of 10 studies;\                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                             *Psychological function/perceived health*: some effect;\                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                             *Function*: ↑ in 4 of 4 on depression and activity measures                                                                                                                                                                                                                                                                                               

  Forster et al[@b47-copd-7-297]                Elderly in long term care                                                                 AT, RT and balance                                 *Mobility* (variety of tests): ↑ in 24 of 35 trials;\                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                             *Strength*: ↑ in 18;\                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                             *Balance*: ↑ in 12 of 16 studies                                                                                                                                                                                                                                                                                                                          

  Chin et al[@b46-copd-7-297]                   Frail, Elderly                                                                            AT, RT and balance                                 *Physical Performance Test*: ↑ in 3 of 4 studies;\                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                             *6MWD*: ↑ in 9 of 17 studies                                                                                                                                                                                                                                                                                                                              

  Rydwik et al[@b51-copd-7-297]                 Institutionalized elderly, multiple diagnoses                                             AT, RT, balance, mobility, gait, ADL               *Strength*: ↑ in 6 of 9 studies;\                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                             *Mobility*: ↑ in 8 of 12 studies;\                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                             *Range of motion*: ↑ in 2 of 3 studies;\                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                             *Gait:* ↑ in 4 of 8 studies;\                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                             *Activities of daily living*: ↑ in 3 of 6 studies                                                                                                                                                                                                                                                                                                         

  Davies et al [@b55-copd-7-297]                HF, severity not an inclusion criterion                                                   AT, RT                                                                                                                                                                                                                                                                                                                                                                                                       *Hospital admissions related to heart failure:* 7/569/RR: 0.72 \[0.52, −0.99\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *QoL using Minnesota Living with Heart Failure Questionnaire:* 6/700/WMD −10.3 \[−15.9, −4.8\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *QoL using all scales:* 9/779/SMD: −0.57 \[0--0.83, −0.31\]

  Hwang et al[@b54-copd-7-297]                  HF, diagnosis based on clinical signs or LVEF \< 40%                                      RT                                                 *6MWD:* 2/40/52 m \[19, 85\]                                                                                                                                                                                                                                                                                                                              

  Hwang and Marwick[@b57-copd-7-297]            HF                                                                                        AT (15) or AT + RT (4)                             *VO~2~* *max:* 16/733/2.86 mL/kg/min \[1.43, 4.29\];\                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                             *Exercise duration:* 7/241/2.00 min \[1.43, 2.57\];\                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                             *6MWD*: 6/628/30.4 m \[6.1, 54.7\]                                                                                                                                                                                                                                                                                                                        

  Chien et al[@b53-copd-7-297]                  HF, diagnosis based on clinical signs or LVEF \< 40%                                      Mostly AT, home-based. RT added in 3/10 studies    *VO~2~* *max:* 7/355/MD 2.71 mL/kg/min \[0.67, 7.74\];\                                                                                                                                                                                                                                                                                                   *Hospitalization due to cardiac events:* 2/143/OR 0.75 \[0.19, 2.92\]
                                                                                                                                                                                             *6MWD:* 5/320/MD 41.09 m \[19.12, 63.06\]                                                                                                                                                                                                                                                                                                                 

  Haykowsky et al[@b56-copd-7-297]              HF, severity not a criterion, clinically stable                                           AT                                                 *VO~2~* *max:* 9/538/WMD 2.98 mL/kg/min \[2.47, 3.49\]                                                                                                                                                                                                                                                                                                    *Ejection fraction:* 9/538/WMD 2.59% \[1.44, 3.74\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *End-diastolic volume:* 5/371/WMD −11.49 mL \[−19.95, −3.02\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *End-systolic volume:* 5/371/WMD −12.87 mL \[−17.80, −7.93\]

  van Tol et al[@b58-copd-7-297]                HF, severity not a criterion for inclusion                                                AT, RT                                             *VO~2~* *max:* 31/1240/MD 2.06 mL/kg/min;\                                                                                                                                                                                                                                                                                                                *End-diastolic volume at rest:* 9/527/WD −3.13 mL;\
                                                                                                                                                                                             *Watts on maximal test:* 19/715/MD 14.3 W;\                                                                                                                                                                                                                                                                                                               *Cardiac output during maximal exercise:* 3/104/WD 2.51 L/min
                                                                                                                                                                                             *Anaerobic threshold:* 13/511/MD 1.91 mL/kg/min;\                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                             *6MWD:* 15/599/MD 46.2 m;\                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                             *HR during maximal exercise:* 18/683/MD 3.5 bpm;\                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                             *SBP during maximal exercise:* 10/382/MD 5.4 mmHg;\                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                             *QoL:* 9/463/MD −9.7 points                                                                                                                                                                                                                                                                                                                               

  Spruit et al[@b61-copd-7-297]                 HF, severity not a criterion for inclusion                                                RT                                                 *Mean peak isotonic strength of upper and lower body*: 1/16/37% improvement;\                                                                                                                                                                                                                                                                             
                                                                                                                                                                                             *Muscle endurance*: 1/16/299% improvement                                                                                                                                                                                                                                                                                                                 

  Cahalin et al[@b60-copd-7-297]                HF, severity not a criterion                                                              RT, with short or long bursts of AT                *Muscle strength, muscle endurance, daily activity, forearm blood flow, performance of heel lift, and QoL* increased and *resting HR* decreased, but no synthesis of data from more than one RCT was provided                                                                                                                                             *Left ventricular ejection fraction, left ventricular fractional shortening, and insulin-stimulated glucose uptake* improved, but no synthesis of data from more than one RCT was provided

  Benton[@b59-copd-7-297]                       HF, severity not a criterion                                                              AT, RT                                             *Muscle strength, muscle endurance, QoL, heart rate during exercise, and forearm blood flow* improved, but no synthesis of data from more than one RCT was provided                                                                                                                                                                                       

  Haykowsky et al[@b65-copd-7-297]              Post-MI                                                                                   AT                                                                                                                                                                                                                                                                                                                                                                                                           Meta-regression analysis shows that exercise training had beneficial effects on LV remodeling in clinically stable post-MI patients with greatest benefits occurring when training starts earlier following MI (from one week) and lasts longer than 3 months\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *Ejection fraction:* Q = 25.48, df = 2, *P* \< 0.01;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *End systolic volume:* Q = 23.89, df = 2, *P* \< 0.005;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *End diastolic volume:* Q = 27.42, df = 2, *P* \< 0.01

  Valkeinen et al[@b68-copd-7-297]              Ischemic heart disease (MI, angina, CABG, PTCA, angioplasty, percutaneous intervention)   AT (majority), RT                                  *VO~2~* *max for aerobic training*: 15/807/SMD 0.67 mL/kg/min \[0.39, 0.94\]; Longer exercise training period (\>6 months) starting soon after a cardiac event (\<3 months) had a significant effect on VO~2~ max in patients with CHD: 7/406/SMD 0.94 mL/kg/min \[0.38, 1.50\] and 11/647/SMD 0.77 mL/kg/min \[0.44, 1.10, *P* \< 0.001\] respectively   

  Cortes et al[@b64-copd-7-297]                 Acute myocardial infarction                                                               In hospital early mobilization                                                                                                                                                                                                                                                                                                                                                                               Trend towards decreased total mortality and non-fatal re-infarction, but n.s

  Jolliffe et al[@b66-copd-7-297]               Coronary heart disease                                                                    AT (majority), RT                                                                                                                                                                                                                                                                                                                                                                                            [Comprehensive cardiac rehabilitation]{.ul}:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *Total cardiac death:* 22/2903/OR 0.75 \[0.59, 0.97\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *Total cholesterol:* 9/1198, −0.65 mmol/L \[−0.75, −0.55\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *LDL cholesterol:* 6/728, −0.61 mmol/L \[−0.73, −0.50\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *Triglycerides:* Small but significant reduction (no numbers)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       [Exercise only]{.ul}:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *Total cardiac death*: 8/2312/OR 0.70 \[0.51, 0.94\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *Total mortality:* 12/2582/OR 0.74 \[0.56, 0.98\]

  Clark et al[@b62-copd-7-297]                  Ischemic heart disease                                                                    AT, RT (no details)                                                                                                                                                                                                                                                                                                                                                                                          [Program with exercise]{.ul}:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *Recurrent MI:* 12/3997/RR 0.62 \[0.44, 0.87\]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       [Exercise only]{.ul}:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *Mortality:* 11/2285/RR 0.72 \[0.54, 0.95\]

  Cornish et al[@b63-copd-7-297]                Ischemic CAD (narrative review)                                                           AT (interval training)                             *Exercise capacity*: 2 studies (of 2) showed ↑ in either 6 MWD, cycle test time, VO~2~ max, time to fatigue and HRrest, while both showed increase in workload                                                                                                                                                                                            

  Oliveira et al[@b67-copd-7-297]               Post-MI, CABG (narrative review)                                                          RT                                                 *Exercise capacity*: 2 of 2 studies showed ↑ in 6MWD; *Muscle strength*: 2 studies (of 2) showed ↑ in muscle strength                                                                                                                                                                                                                                     

  Watson et al[@b69-copd-7-297]                 PVD                                                                                       AT, RT                                             *Maximal walking time*: 7/255/MD: 5.1 \[4.5, 5.7\];\                                                                                                                                                                                                                                                                                                      *Pain-free walking time time*: 3/150, MD: 2.9 min \[2.5, 3.3\];\
                                                                                                                                                                                             *Maximal walking distance*: 6/391, MD: 113.20 M \[95.0, 131.4\]                                                                                                                                                                                                                                                                                           *Pain-free walking distance*: 6/322, MD: 82.2 M \[71.7, 92.7\]

  Wind and Koelemay[@b70-copd-7-297]            PVD                                                                                       AT                                                 *Walking distance:* 9/499, WMD: 155.8 M \[80.8, 230.7\]                                                                                                                                                                                                                                                                                                   *Pain free walking distance*: 8/409, WMD: 81.3 M \[35.5, 127.1\]

  Dickinson et al[@b73-copd-7-297]              Hypertension                                                                              AT                                                 *SBP*: 21/1346/MD: −6.1 mmHg \[−10.1, −2.1; I^2^ = 87%\];\                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                             *DBP*: 21/1346/MD: −3.0 mmHg \[−4.9, −1.1; I^2^ = 74%\]                                                                                                                                                                                                                                                                                                   

  Cornelissen and Fagard[@b72-copd-7-297]       Hypertension                                                                              AT                                                 *VO~2~* *max*: 17/279/WMD 4.4 mL/kg/min \[3.7, 5.1\];\                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                             *HR*: 23/340/WMD −4.5 bpm \[−6.5; −2.6\];\                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                             *SBP*: 30/492/WMD −6.9 mmHg \[−9.1; −4.6\];\                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                             *DBP*: 30/492/WMD −4.9 mmHg \[−6.5; −3.3\].                                                                                                                                                                                                                                                                                                               

  Whelton et al[@b74-copd-7-297]                Hypertension                                                                              AT                                                 *SBP*: 15/NR/ES −4.94 mmHg \[−7.17, −2.70\];\                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                             *DBP*: 13/NR/ES −3.73 mmHg \[−5.69, −1.77\]                                                                                                                                                                                                                                                                                                               

  Kelley et al[@b71-copd-7-297]                 Hypertension                                                                              AT                                                 *SBP:* −6 mmHg \[−8, −3\] (number of trials/subjects NR);\                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                             *DBP:* −5 mmHg \[−7, −3\] (number of trials/subjects NR)                                                                                                                                                                                                                                                                                                  

  Shaw et al[@b76-copd-7-297]                   Obesity                                                                                   AT                                                 *DBP*: 2/259/WMD −2.09 mmHg \[−3.68, −0.51\]                                                                                                                                                                                                                                                                                                              *Triglycerides*: 3/348/WMD −0.18 mmol/l \[−0.31, −0.05\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *Fasting glucose*: 2/273/WMD −0.17 mmol/l \[−0.30, −0.05\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *HDL*: 3/348/WMD 0.06 mmol/l \[0.03, 0.09\]

  Witham and Avenell[@b75-copd-7-297]           Obese postmenopausal women                                                                AT, RT                                             *VO~2~* *max*: increase by 11.7% in the intervention group and 0.7% in the control group at 12 months (*P* \< 0.001)                                                                                                                                                                                                                                      

  Devos-Comby et al[@b79-copd-7-297]            OA                                                                                        AT, RT, and balance                                *Direct measures of impairment (walking distance test, timed chair rise, time getting out of a car, balance tests, or gait):* 11/740/SES 0.15 \[0.08, 0.23\]                                                                                                                                                                                              *Combined physical outcomes (Scales of physical disability, discomfort, pain, function, mobility* ie, *AIMS)*: 12/808/SES: 0.29 \[0.23, 0.36\].

  Lange et al[@b80-copd-7-297]                  Knee OA                                                                                   RT                                                 *Strength*: ↑ in 9 of 14 studies; *Maximal gait speed*: ↑ in 4 of 4 studies; *Maximal stair climb/descent*: ↑ in 3 of 5 studies                                                                                                                                                                                                                           *Pain*: ↑ in 10 of 18 studies; *Physical disability*: ↑ in 11 of 14 studies; *Physical self efficacy*: ↑ in 2 of 2 studies

  Ottawa Panel[@b77-copd-7-297]                 OA                                                                                        AT, RT                                             *Strength, aerobic capacity, and functional status:* different levels of evidence support various types of strengthening, mobility and flexibility exercises based on RCTs but no synthesis of data from more than one RCT was provided                                                                                                                   *Pain:* different levels of evidence from RCTs show that different types of exercise decrease pain. No synthesis of data from more than one RCT was provided

  Brosseau et al[@b78-copd-7-297]               OA                                                                                        AT                                                 *Aerobic capacity, timed walk distance, walk velocity*: ↑ in RCTs but no synthesis of data from more than one RCT was provided                                                                                                                                                                                                                            

  Pelland et al[@b81-copd-7-297]                OA -- most knee or hip                                                                    Mainly RT                                          *Strength, function and QoL:* improves, but no synthesis of data from more than one RCT was provided                                                                                                                                                                                                                                                      *Pain:* decreases, but no synthesis of data from more than one RCT was provided

  Li et al[@b83-copd-7-297]                     Osteoporosis or osteopenia; severity not an inclusion criteria                            RT or combined stretch/strength/balance programs   *QoL:* All domains of SF36 were significantly improved for all 4 studies. Scores out of 100.\                                                                                                                                                                                                                                                             
                                                                                                                                                                                             *Physical function:* 5/288/WMD 2.77 \[2.27, 3.37\]; *Pain:* 5/288/WMD 4.95 \[3.52, 8.70\];\                                                                                                                                                                                                                                                               
                                                                                                                                                                                             *Role Physical:* 2/78/WMD 12.41 \[0.35, 24.46\];\                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                             *Vitality:* 2/78/WMD 11.11 \[3.99, 18.22\]\                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                             Subgroup analysis showed that programs that combined programs improved QoL physical function and pain scores more than strengthening alone                                                                                                                                                                                                                

  De Kam et al[@b82-copd-7-297]                 Osteoporosis or osteopenia                                                                AT, RT, Balance, Gait                              Improvements in: TUG, standing up and walking around cones, U/E strength, posturagraphy; figure 8 walking; L/E strength; trunk strength; step test; lateral reach; walking velocity; balance performance                                                                                                                                                  Improvements in: spine BMD, hip BMD, femur BMD, fall-related fractures; radius BMD, calcaneus BMD, fall risk reduction; tibia BMD, falls incidence; vertebral height

  Chudyk and Petrella[@b85-copd-7-297]          Type 2 DM                                                                                 AT 21 RCT\                                         *SBP:*\                                                                                                                                                                                                                                                                                                                                                   *HbA~1c~*\
                                                                                                                                          AT + RT                                            AT: −6.1 mmHg \[−10.8, −1.4\];\                                                                                                                                                                                                                                                                                                                           AT: WMD: −0.62% \[−0.98, −0.27\];\
                                                                                                                                                                                             AT + RT: −3.6 mmHg \[−6.9, −0.2\]                                                                                                                                                                                                                                                                                                                         AT + RT: WMD: −0.67% \[−0.93, −0.40\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *Triglycerides*\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       AT: WMD: −0.29 mmol/L \[−0.48, −0.11\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       AT + RT: WMD: −0.30 mmol/L \[−0.57, −0.02\].

  Umpierre et al[@b90-copd-7-297]               Type 2 DM                                                                                 AT, RT, AT + RT                                                                                                                                                                                                                                                                                                                                                                                              *HbA~1c~*\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       AT: 18/848/WMD: −0.73% \[−1.06, −0.40\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       RT: 4/261/WMD: −0.57% \[−1.14, −0.01\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       AT + RT: 7/404/WMD: −0.51% \[−0.79, −0.23\].

  Irvine and Taylor[@b86-copd-7-297]            Type 2 DM                                                                                 RT                                                 *Strength*: 4/NR/SES: 0.95 \[0.58, 1.31\]                                                                                                                                                                                                                                                                                                                 *HbA~1c~*: 7/NR/SES: −0.25 \[−0.47,−0.03\]

  Thomas et al[@b89-copd-7-297]                 Type 2 DM                                                                                 AT or RT                                           *VO~2~* *max*: 3/95/MD: 4.8 mL/kg/min \[2.6, 7.1\]                                                                                                                                                                                                                                                                                                        *HbA~1c~*: 13/361/MD: −0.62% \[−0.91,−0.33\].

  Kelley and Kelley[@b87-copd-7-297]            Type 2 DM                                                                                 AT                                                                                                                                                                                                                                                                                                                                                                                                           *Low density lipoprotein*: WMD: −6.4 mg/dl \[−11.8, −1.1\]

  Snowling and Hopkin[@b88-copd-7-297]          Type 2 DM                                                                                 AT, RT, or A + RT                                  A + RT: *SBP*: 5/NR/WMD: −5.6 mmHg \[−9.3, −1.8\];\                                                                                                                                                                                                                                                                                                       *HbA~1c~*:\
                                                                                                                                                                                             *DBP*: 5/NR/WMD: −5.5 mmHg \[−9.9, −1.1\].                                                                                                                                                                                                                                                                                                                AT: 17/NR/WMD: −0.7% \[−1.0, −0.4\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       RT: 6/NR/WMD: −0.5% \[−1.0, −0.1\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       A + RT: 5/NR/WMD: −0.8% \[−1.3, −0.2\].

  Boulé et al[@b84-copd-7-297]                  Type 2 DM                                                                                 AT                                                 *VO~2~* *max*: 9/266/SES: 0.53 \[0.18, 0.88\]                                                                                                                                                                                                                                                                                                             *HbA~1c~*: 8/NR/WMD: −0.71 \[−1.1, −0.32\]

  O'Brien et al[@b91-copd-7-297]                HIV -- range of severity                                                                  AT                                                 *VO~2~* *max*: 5/276/WMD: 2.6 mL/kg/min \[1.2, 4.1\];\                                                                                                                                                                                                                                                                                                    Interval AT:\
                                                                                                                                                                                             *Strength*: ↑ in 5 of 6 studies                                                                                                                                                                                                                                                                                                                           *CD4 cell counts*: 2/45/WMD: 69.6 cells/mm^3^ \[14.1, 125.1\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       AT: *Profile of moods*: 2/65/WMD: −7.7 \[−13.5, −1.9\].

  Krogh et al[@b93-copd-7-297]                  Depression                                                                                9 AT; 3 RT; 1 A + RT                                                                                                                                                                                                                                                                                                                                                                                         *Depressive symptoms:* 13/272/SES: −0.40 \[−0.66, −0.14\]

  Herring et al[@b94-copd-7-297]                Anxiety and chronic illness                                                               AT, RT, balance                                                                                                                                                                                                                                                                                                                                                                                              *Anxiety symptoms:* 38/NR/SES: 0.29 \[0.23, 0.36\]

  Mead et al[@b96-copd-7-297]                   Depression                                                                                AT, RT, A + RT                                                                                                                                                                                                                                                                                                                                                                                               *Depression symptoms*\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       AT: 17/640/SES: −0.63 \[−0.95, −0.30\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       RT: 2/69/SES: −1.34 \[−2.07, −0.61\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       A + RT: 4/198/SES: −1.47 \[−2.56, −0.37\]

  Rethorst et al[@b95-copd-7-297]               Depression                                                                                AT, RT, AT + RT                                                                                                                                                                                                                                                                                                                                                                                              *Depression scores:* 58/2982/ES: −0.80 \[0.92, 0.67\].

  Lawlor and Hopker[@b92-copd-7-297]            Depression                                                                                AT                                                                                                                                                                                                                                                                                                                                                                                                           *Depressive symptoms:* 9/461/SES: −1.1 \[−1.5 to −0.6\];\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *Beck depression*: 9/461/WMD: −7.3 \[−10.0, −4.6\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** WMD (weighted mean difference) is a calculation that provides an average mean difference of studies by weighting the means more highly when the n is larger and the variance is smaller. If the WMD is provided, the unit value for the measure is shown. SES (standardized effect size) is usually calculated by determining the difference between the pre-post values for the intervention and control groups and dividing this difference by the respective standard deviation of differences for the intervention group or the average SD of the differences for both groups.

**Abbreviations:** AT, aerobic training; BMD, bone mineral density; DBP, diastolic blood pressure; HbA~1c~, glycosylated hemoglobin; MD, mean difference; OR, odds ratio; QoL, quality of life; RR, rate ratio; RT, resistance training; SES, standardized effect size; 6 MWD, six-minute walking distance; SBP, systolic blood pressure; TUG: timed up-and-go; WMD, weighted mean difference.
